Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...
In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback